



Luxembourg, 06 November 2024

Environmental and Social Completion Sheet (ESCS)

Overview

Project Name:	PHARMACEUTICAL RDI & INVESTMENTS
Project Number:	2020-0266
Country:	Spain
Project Description:	Financing of the promoter's pharmaceutical RDI and expansion investments in Spain.

Summary of Environmental and Social Assessment at Completion

EIB notes the following Environmental and Social performance and key outcomes at Project Completion.

No significant environmental or social issues were noted. The project involved investments in i) R&D activities; ii) R&D laboratory equipment; iii) acquisition of new machines to increase manufacturing capacity in the promoter's manufacturing site in San Agustín del Guadalix, near Madrid, iv) installation of solar panels on the above manufacturing site, following obtaining the relevant permits; and v) relevant IT solutions. The R&D activities are a central part of the promoter's operations and were embedded in the existing organisational and management structure. The Capex investments took place in the already authorised existing facilities. The project activities are not listed in any annexes of the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. They were conducted in pre-authorized existing facilities, and the scope of these facilities will remain unchanged due to the project.

Summary opinion of Environmental and Social aspects at completion:

Based on reports from the promoter and a site visit by the EIB team during implementation, the EIB believes that the project has been carried out in accordance with the EIB Environmental and Social Standards that were applicable at the time of appraisal.